TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with clinically significant vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant physical examination abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant weight abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with clinically significant laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Surgical Field Visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood boron level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average score of the WIQ specific self-questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of subjects classified into each of the GOLD 2016 comprehensive classification system groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: To assess the disease severity by CAT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No of subjects with exacerbation history and hospitalization for exacerbation in preceding year
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional reactions (quality of contacts)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional reactions (numbers of contacts)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement in signs and symptoms of allergic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Alive After 5 Years From Index Date
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Alive After 6 Years From Index Date
Endpoint domain: Mortality/survival
Primary endpoint: Train of four (TOF) test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Mean Pressure Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Value of Narco-trend Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of whole-body MRI-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of whole-body MRI-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive predictive value of whole-body MRI-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative predictive value of whole-body MRI-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin Secretion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Left Atrial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antibody response (geometric mean titer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mRS at 90 days after thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in serum LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical improvement or failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major intubation-related complication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Days Being Intubated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RVIP Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RVIP Total Hits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RVIP Total Correct Rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immunogenicity of Recombinant Hepatitis B Vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of eligible patients completing the transplant procedure successfully
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Treatment-related mortality of < 25% at 2 years following transplant
Endpoint domain: Mortality/survival
Primary endpoint: Executive Functions (Hearts and Flowers Flanker Tasks)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive Functions (Stroop Colored Word Test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Executive Functions (BRIEF Parent Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neurological toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Utilization of Extracorporeal membrane oxygenation (ECMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Onset of Syncope/Near Syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of dementia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to next disease level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Drug Events before progression
Endpoint domain: Adverse events/effects
Primary endpoint: Change in percentage of total fatty acids for PUFA groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastro-intestinal tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Subjects Experiencing Safety Composite Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients With Chronic Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and duration of grade 3/4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time frame of ANC recovery to 2.0×10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients that die at 30, 90 and 365 days after index surgery
Endpoint domain: Mortality/survival
Primary endpoint: Photoirritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Photosensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Member rescue rate
Endpoint domain: Mortality/survival
Primary endpoint: Time to Delivery of Fetus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: numbers of lidocaine rescues for severe injection pain
Endpoint domain: Adverse events/effects
Primary endpoint: incidences of injection pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition to substance abuse treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in the severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-related symptoms (ESAS and PG-SGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Triceps skin fold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y/X sperm ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of Radiotherapy treatment delays
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Surviving to Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction With Mail-Order Dispensing of Medication Abortion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Would Use Mail-Order Dispensing Again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood-based genetic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Cumulative Daily Fentanyl Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Effective Dose (MEPD) of single agent decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of the combination of valproic acid with decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative and quantitative toxicities of decitabine and valproic acid
Endpoint domain: Adverse events/effects
Primary endpoint: size of infiltrate or scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal structural integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events using a Quality of Life scale
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events using a Visual Analog Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Correct Word Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: 6 minute walk test change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal pro-brain natriuretic peptide(NT-Pro BNP) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1-10 Borg Rating of Perceived Exertion Scale change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline on Posttraumatic Stress-Total (PTS-T) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: American College of Rheumatology 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Composite Removable Sinus Stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Classified as Heat-Intolerant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of MK0633
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophilic Cationic Protein biomarker level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: morphology of the bleb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: function of the bleb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skindex 29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: sweet taste recognition threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salt taste recognition threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete or partial remission of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concussion Identification Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ImPACT test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear osmolarity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry eye symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric Mean Titers (GMTs) of Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT Ratio after Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rates after Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Faecal bulk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Information Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fasted HDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness and tolerance of therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Possible hospitalisation rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in extent of damage and acceleration of immune system recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delay of and reduction in recurrent viremia compared to historical controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of resolution of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Contiguous Activated Voxels in DLPFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants and Prescribing Physicians Providing Correct Responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of Severe (Grade 4) Neutropenia in Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With at Least 1 Occurrence of Severe (Grade 4) Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum free PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Side branch region ischemia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture movement postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual disease at re-staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in Circumferential Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pedal force of affected leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal epithelial cell secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention Rate of Eslicarbazepine Acetate (ESL)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of newborns receiving HIV diagnosis and treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with decreased urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Moderate or severe exacerbations of COPD requiring hospitalization or treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gait Speed (Timed 25 Foot Walk)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single Leg Stance (SLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of thrombi within each branch of the pulmonary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Impairment in the Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed recall of a word list
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delayed Recall of Names-Face Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of unprotected vaginal or anal sex with perceived high risk male partner
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Grading of Lower Eyelid Scar Contracture (GLESCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading of lower eyelid malpositioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nerve morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of radiosurgical ablation in terms of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of radiosurgical ablation in terms of radiographic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion and clearance rates of the marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Ocular Surface Disease Index Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of levofloxacin, moxifloxacin or gatifloxacin in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defibrillator threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid Intima-media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of Specific Phobia (acrophobia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Score of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in level of catecholamines in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: wheelchair independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of direct serum bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Randomization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Follow-up retention rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improving of sleeping quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 3-Month Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-Month Usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3-Month Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-Month Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Surgical Technical Skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ratio of maximum serum concentration (Cmax) of total iron in fasted condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of maximum serum concentration (Cmax) of total iron in combined periods of fed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of area under the curve (AUClast) of total serum iron in combined period of fasted condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of area under the curve (AUClast) of total serum iron in combined period of fed condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All-causes mortality
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of sexual dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulnohumeral flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nitric oxide gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease of the felt pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modification of the kyphotic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Potential Sensitisation Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical improvement score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Microglia Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain fMRI image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in self-care behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances